

Pegfilgrastim– Biosimilar Insight, 2022

<https://marketpublishers.com/r/PC047B1269B7EN.html>

Date: January 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: PC047B1269B7EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Pegfilgrastim– Biosimilar 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Pegfilgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Pegfilgrastim Understanding

Pegfilgrastim: Overview

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. It is used to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Some patients with greater risk factors may develop febrile neutropenia from myelosuppressive therapy and are susceptible to an increased risk of developing infections. Although the risk of developing febrile neutropenia is less than 20% in many readily used chemotherapy regimens, infections pose risks of hospitalization and mortalities. Due to the relatively short circulating half-life of filgrastim, a 20 kDa PEG moiety was covalently conjugated to the N-terminus of filgrastim (at the methionine residue) to develop a longer acting version of

the drug. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim.

Pegfilgrastim Biosimilars: Drugs Chapters

This segment of the Pegfilgrastim report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pegfilgrastim Biosimilars: Marketed Drugs

Nyvepria: Pfizer

Nyvepria is a biosimilar to Neulasta, is approved by the FDA to help reduce the chance of infection due to a low white blood cell count in people with non-myeloid cancer who receive anti-cancer medicines, like chemotherapy, that can cause fever and low white blood cell count. This condition, known as febrile neutropenia, is a common side effect of many types of chemotherapy and lowers the body's ability to defend itself against infections.

Further product details are provided in the report.....

Pegfilgrastim Biosimilars: Emerging Drugs

PF-06881894: Pfizer

PF-06881894 is a potential biosimilar to Neulasta (Pegfilgrastim) which was initially being developed by Hospira pharma and currently is being developed by Pfizer. The drug is currently in registration phase of development for the treatment of Neutropenia.

Further product details are provided in the report.....

Pegfilgrastim: Therapeutic Assessment

This segment of the report provides insights about the different Pegfilgrastim biosimilars segregated based on following parameters that define the scope of the report, such as:

Major Players in Pegfilgrastim

There are approx. 20+ key companies which are developing the therapies for Pegfilgrastim.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Marketed stage products

Late stage products (BLA Filed and Phase III)

Mid-stage products (Phase II and

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Pegfilgrastim pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibodies

Peptide

Protein

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pegfilgrastim: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Pegfilgrastim biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pegfilgrastim biosimilar drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pegfilgrastim R&D. The therapies under development are focused on novel approaches to treat/improve Pegfilgrastim.

In June 2020, Pfizer announced the United States (U.S.) Food and Drug Administration (FDA) has approved Nyvepria (pegfilgrastim-apgf), a biosimilar to Neulasta (pegfilgrastim). NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

In February 2020, Pfizer confirms the Preregistration for Neutropenia in European Union and in USA.

In September 2015, Pfizer announced that it has completed its acquisition of Hospira, Inc

Pegfilgrastim Biosimilars Report Insights

Pegfilgrastim Biosimilar Pipeline Analysis

Therapeutic Assessment

Sales Assessment

Unmet Needs

Impact of Drugs

Pegfilgrastim Biosimilar Report Assessment

Marketed Product profiles

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Sales Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Pegfilgrastim Biosimilars?

How many Pegfilgrastim biosimilars are developed by each company?

How many emerging biosimilars are in mid-stage, and late-stage?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pegfilgrastim biosimilars therapeutics?

What are the clinical studies going on for Pegfilgrastim biosimilars and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Merck & Co

Zydus Cadila

Virchow Group

USV

Sandoz

Reliance Life Sciences

Ratiopharm

PharmaEssentia

Pfizer

Pfenex

Nanogen Biopharmaceutical

Mylan

Mundipharma Biologics

Lupin

Jiangsu Hengrui Medicine Co

Intas Biopharmaceuticals

Hospira

Harvest Moon Pharmaceuticals

Hangzhou Jiuyuan Gene Engineering

Gene Techno Science

Gedeon Richter

Fresenius Kabi

Eurofarma Laboratorios

ERA Consulting (Coherus Biosciences)

Emcure Pharmaceuticals

Dr Reddy's Laboratories

Dong-A ST

Coherus Biosciences

CinnaGen

Cinfa Biotech

Chong Kun Dang

Biocure Technology

Biocon

Apotex

Accord Healthcare

Key Products

MK-6302

Peg G-CSF

PEG Neutrogen

Grasustek

LA-EP2006/Ziextenzo

R-TPR-029

Filgrastim ratiopharm

PEG-GCSF

PF-06881894

PF-529

PEGCYTE

Fulphila

Cegfila

Lupifil-P

HHPG-19K

Neupeg

HSP-130

GBS 010

RGB-02

MSB-11455

Recombinant pegfilgrastim

Udenyca

DRL_PG/ Peg-grafeel

Dulastin

Udenyca

PegaGen

B12019/Pelmeg

CKD-12101

Neutropeg (Apo-Peg)

Pelgraz

Contents

1. KEY INSIGHTS

2. PEGFILGRASTIM BIOSIMILARS: SNAPSHOT

3. EXECUTIVE SUMMARY

3.1. Overview

3.2. The Basics of Biologics.

3.3. Biosimilars are not the Same as Generic Drugs

3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?

3.5. What Patients Need to Know About Biosimilars

4. REGULATORY OUTLOOK FOR BIOSIMILARS

4.1. North America

4.1.1. US

4.1.2. Canada

4.2. Europe

4.3. Asia Pacific

4.3.1. China

4.3.2. India

4.3.3. Japan

4.3.4. South Korea

4.3.5. Australia

4.4. Rest Of The World

4.4.1. Brazil

4.4.2. Mexico

4.4.3. Argentina

4.4.4. Saudi Arabia

*More Countries would be added in the final report

5. PEGFILGRASTIM (REFERENCE PRODUCT: NEULASTA)

5.1. Drug Profile

5.2. Product Overview

5.3. Regulatory Approvals and Launch

5.4. Indications

- 5.5. Mechanism of Action
- 5.6. Dosage and Administration
- 5.7. Dosage and Strengths
- 5.8. Dose Modification
- 5.9. Route of Synthesis
- 5.10. Pharmacology
- 5.11. Pharmacodynamics
- 5.12. Pharmacokinetics
- 5.13. Adverse Reactions
- 5.14. Product Snapshot
- 5.15. Development Milestones

6. RESEARCH AND DEVELOPMENT

- 6.1. Clinical Trials Information
- 6.2. Safety and Efficacy

7. NEULASTA BIOSIMILAR: EMERGING OPPORTUNITIES

8. PEGFILGRASTIM: BIOSIMILARS ASSESSMENT

- 8.1. Assessment by Product Type
- 8.2. Assessment by Route of Administration
- 8.3. Assessment by Molecule type
- 8.4. Sales Assessment

9. PEGFILGRASTIM BIOSIMILARS PROFILES: BY COMPANY

- 9.1.1. Pfizer
 - 9.1.1.1. Nyvepria: Pfizer
 - 9.1.1.1.1. Product Information
 - 9.1.1.1.2. Research and Development
 - 9.1.1.1.3. Other Development Activities
 - 9.1.1.1.4. General Description Table
 - 9.1.1.2. PF-06881894: Pfizer
 - 9.1.1.2.1. Product Information
 - 9.1.1.2.2. Research and Development
 - 9.1.1.2.3. Other Development Activities
 - 9.1.1.2.4. General Description Table

9.1.2. Mylan

9.1.2.1. Fulphila: Mylan

9.1.2.1.1. Product Information

9.1.2.1.2. Research and Development

9.1.2.1.3. Other Development Activities

9.1.2.1.4. General Description Table

9.1.3. USV

9.1.3.1. Grasustek: USV

9.1.3.1.1. Product Information

9.1.3.1.2. Research and Development

9.1.3.1.3. Other Development Activities

9.1.3.1.4. General Description Table

*More Companies and products would be added in the final report

10. PEGFILGRASTIM BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY

11. PEGFILGRASTIM BIOSIMILARS: COMPETITIVE LANDSCAPE

11.1.1. Overview

11.1.2. Market Share Analysis

11.1.3. Competitive Scenario

11.1.3.1. Product Launches and approval

11.1.3.2. Partnerships, Collaborations and Agreements

11.1.3.3. Acquisitions

11.1.3.4. Expansions

11.1.3.5. Patent Expiration of Biologics

*More information would be added in the final report

12. MARKET DRIVERS

13. MARKET BARRIERS

14. SWOT ANALYSIS

15. APPENDIX

15.1. Research Methodology

15.1.1. Coverage

15.1.2. Secondary Research

16. BIBLIOGRAPHY

17. DELVEINSIGHT CAPABILITIES

18. DISCLAIMER

19. ABOUT DELVEINSIGHT

I would like to order

Product name: Pegfilgrastim– Biosimilar Insight, 2022

Product link: <https://marketpublishers.com/r/PC047B1269B7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PC047B1269B7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970